Table 3. Number of Foxp3+ and CD8+ T-cells and CD8+/Foxp3+ cell ratio by clinical outcome and tumor HPV status.
| Clinical outcome | Unadjusted effectsb | Effectsb adjusted for HPV status | |||||
| Factor | HPV statusa | Good (n=42) | Poor (n=41) | Mean difference (95% CI) | P-valuec | Mean difference (95% CI) | P-valuec |
| Mean CD8+ TIL value | Positive | 61.4 (31) | 21.0 (21) | 40.4 (15.8 to 65.0) | 0.002 | ||
| Negative | 19.4 (11) | 4.7 (20) | 14.7 (6.2 to 23.1) | 0.001 | |||
| 0.12d | |||||||
| Total | 50.4 (42) | 12.8 (41) | 37.6 (21.3 to 53.8) | <0.001 | 30.9 (15.1 to 46.7) | <0.001 | |
| Mean Foxp3+ TIL value | Positive | 33.7 (31) | 32.5 (21) | 1.2 (−16.0 to 18.4) | 0.89 | ||
| Negative | 11.6 (11) | 16.4 (20) | −4.7 (−12.2 to 21.6) | 0.57 | |||
| 0.65d | |||||||
| Total | 27.9 (42) | 24.6 (41) | 3.3 (−9.2 to 15.8) | 0.60 | −0.95 (−13.3 to 11.4) | 0.88 | |
| Mean CD8+/Foxp3+ ratio | Positive | 3.0 (31) | 1.6 (21) | 1.4 (−0.4 to 3.1) | 0.13 | ||
| Negative | 8.2 (11) | 1.1 (20) | 7.0 (−1.5 to 15.6) | 0.10 | |||
| 0.10d | |||||||
| Total | 4.3 (42) | 1.4 (41) | 3.0 (−0.3 to 6.2) | 0.07 | 3.5 (0.15 to 6.8) | 0.04 | |
a
HPV data obtained from previous studies (3, 6, 25).
b
Effects of HPV-status (negative versus positive) estimated using linear regression.
c
P-values refers to F-tests.
d
Overall test for effect modification (i.e. interaction between HPV status and clinical outcome).